Press release
Atopic Dermatitis Pipeline and Clinical Trials 2023: Drugs and Companies, Therapies, Mechanism of Action, Route of Administration, and Developments by DelveInsight
Atopic Dermatitis Pipeline
The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for sample page @ https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Atopic Dermatitis Pipeline Report:
• Companies across the globe are diligently working toward developing novel Atopic Dermatitis treatment therapies with a considerable amount of success over the years.
• Leading Atopic Dermatitis companies working in the market are Pfizer, Kymera Therapeutics, Benevolent AI, AstraZeneca, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others, developing therapies for the Atopic Dermatitis treatment
• Promising Atopic Dermatitis therapies such as - PF 07242813, KT-474, BEN2293, MEDI3506, SB011, Tradipitant, Roflumilast, and others are expected to have a significant impact on the Atopic Dermatitis market in the coming years.
• In November 2022, Alphyn Biologics announced that it had completed the first cohort of its Phase IIa clinical trial of AB-101a, a topical therapeutic candidate for mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 years old. The first cohort enrolled AD patients without bacterial infection, which is sometimes associated with the disease. Top-line results are expected in approximately eight weeks
• In September 2022, selectION announced that it has begun dosing patients in a Phase Ib trial to evaluate safety and efficacy, including duration of clinical benefit, of si-544 in patients with mild to severe atopic dermatitis.
• In July 2022, Connect Biopharma Holdings announced it has been informed by the Center for Drug Evaluation of the National Medical Products Administration (CDE), that it can conduct primary analysis of its ongoing pivotal trial for its lead product candidate CBP-201 to treat adult patients with moderate-to-severe atopic dermatitis (AD) based on the 255 patients. As a result, Connect Biopharma plans to report this trial's top-line results by year-end, earlier than originally planned.
Atopic Dermatitis Overview
Atopic Dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word 'dermatitis,' 'derm' means skin' and 'itis' means 'inflammation.
Request for a free sample report @ https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Route of Administration
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Atopic Dermatitis Pipeline Therapeutics Assessment
• Atopic Dermatitis Assessment by Product Type
• Atopic Dermatitis By Stage and Product Type
• Atopic Dermatitis Assessment by Route of Administration
• Atopic Dermatitis By Stage and Route of Administration
• Atopic Dermatitis Assessment by Molecule Type
• Atopic Dermatitis by Stage and Molecule Type
Request for a free sample report @ https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's Atopic Dermatitis Pipeline Report covers around 100+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Some of the key companies in the Atopic Dermatitis Therapeutics Market include:
Some of the Atopic Dermatitis companies working in the market are - Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, Evommune, Inc., Fresh Tracks Therapeutics, Biosion, Chia Tai Tianqing Pharmaceutical, Reistone Biopharma Company Limited, JW Pharmaceutical, Oneness Biotech, Alphyn Biologics, selectION, UNION Therapeutics, Ichnos Sciences, and others.
Emerging Atopic Dermatitis Drugs Under Different Phases of Clinical Development Include:
• PF 07242813: Pfizer
• KT-474: Kymera Therapeutics
• BEN2293: Benevolent AI
• MEDI3506: AstraZeneca
• SB011: Sterna Biologicals
• Tradipitant: Vanda Pharmaceuticals
• Roflumilast: Arcutis Biotherapeutics
Get a Free Sample PDF Report to know more about Atopic Dermatitis Pipeline Therapeutic Assessment @ https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Atopic Dermatitis Pipeline Market Drivers
• Rising prevalence of Atopic Dermatitis
• Escalating expenditure on health care
• Potential Emerging Therapies
Atopic Dermatitis Pipeline Market Barriers
• Over-the-counter medications
• Outdated treatment recommendations
• Poor prognosis and treatment adherence
Scope of Atopic Dermatitis Pipeline Drug Insight
• Coverage: Global
• Key Atopic Dermatitis Companies: Pfizer, Kymera Therapeutics, Benevolent AI, AstraZeneca, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others
• Key Atopic Dermatitis Therapies: PF 07242813, KT-474, BEN2293, MEDI3506, SB011, Tradipitant, Roflumilast, and others
• Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies
• Atopic Dermatitis Market Dynamics: Atopic Dermatitis market drivers and Atopic Dermatitis market barriers
Request for Sample PDF Report for Atopic Dermatitis Pipeline Assessment and clinical trials @ https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Atopic Dermatitis Report Introduction
2. Atopic Dermatitis Executive Summary
3. Atopic Dermatitis Overview
4. Atopic Dermatitis- Analytical Perspective In-depth Commercial Assessment
5. Atopic Dermatitis Pipeline Therapeutics
6. Atopic Dermatitis Late Stage Products (Phase II/III)
7. Atopic Dermatitis Mid Stage Products (Phase II)
8. Atopic Dermatitis Early Stage Products (Phase I)
9. Atopic Dermatitis Preclinical Stage Products
10. Atopic Dermatitis Therapeutics Assessment
11. Atopic Dermatitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Atopic Dermatitis Key Companies
14. Atopic Dermatitis Key Products
15. Atopic Dermatitis Unmet Needs
16 . Atopic Dermatitis Market Drivers and Barriers
17. Atopic Dermatitis Future Perspectives and Conclusion
18. Atopic Dermatitis Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports
• Familial Primary Pulmonary Hypertension Market : https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Astigmatism Market : https://www.delveinsight.com/report-store/astigmatism-market
• Neurostimulation Devices Market : https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Opioid Induced Constipation Market : https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Nonalcoholic Steatohepatitis Market : https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market
• Meningioma Market : https://www.delveinsight.com/report-store/meningioma-market
• Pediatric Growth Hormone Deficiency Pghd Market : https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
• Progressive Multifocal Leukoencephalopathy Market : https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Osteoarthritis Market : https://www.delveinsight.com/report-store/osteoarthritis-market
• Actinic Keratosis Market : https://www.delveinsight.com/report-store/actinic-keratosis-market
• Blood Gas And Electrolyte Analyzers Market : https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cerebral Aneurysm Market : https://www.delveinsight.com/report-store/cerebral-aneurysm-market
• Neurovascular Devices Market : https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Capnography Device Market : https://www.delveinsight.com/report-store/capnography-devices-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
Contact Us:
Ankit Nigam
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Pipeline and Clinical Trials 2023: Drugs and Companies, Therapies, Mechanism of Action, Route of Administration, and Developments by DelveInsight here
News-ID: 3070981 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Atopic
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
Atopic Dermatitis (Atopic Eczema) Treatment Market Business Growth And Industry …
Precision Business Insights published a research report on “Atopic Dermatitis (Atopic Eczema) Treatment Market by Drug type (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Phosphodiesterase type 4 (PDE-4) Inhibitors, Antibiotics, Antihistamines, Emollients), Route of administration (Oral, Topical, Parenteral), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography - Global/Region/Country Forecast to 2027”.
In people who suffer from atopic dermatitis, allergies play a big influence. When the patient is exposed to…
